Telomir Pharmaceuticals Secures $3 Million Investment to Advance Novel Age-Reversal Drug for Rare Diseases
Telomir Pharmaceuticals has secured $3 million in premium equity financing from its largest shareholder to advance Telomir-1, a first-in-class age-reversal molecule, toward an IND submission for rare disease indications by year-end.
Telomir Pharmaceuticals Develops Novel Silver(II) Antimicrobial to Combat Drug-Resistant Infections
Telomir Pharmaceuticals has developed Telomir-Ag2, a stabilized Silver(II) complex showing potent activity against drug-resistant pathogens including MARSA, targeting the $30B+ antimicrobial market.
Telomir-1 Shows Complete Reversal of Oxidative Stress in Breakthrough Preclinical Study
Telomir Pharmaceuticals' novel compound Telomir-1 demonstrates complete reversal of copper-induced oxidative stress in human cell lines, showing potential for treating age-related diseases and neurological disorders.
Telomir Pharmaceuticals' Telomir-1 Shows Copper-Binding Potential for Wilson's Disease Treatment
Telomir Pharmaceuticals' Telomir-1 demonstrated significant copper-binding affinity in preclinical studies, suggesting its potential for treating Wilson's disease.